Table 1.

RCTs comparing hormonal treatment at diagnosis versus placebo.

Ref	Comparison	Number of RCTs	Population	Outcome	Results (95% CI)
	Gonadorelin analogues v placebo	1	63 women with endometriosis	Symptom severity at 3 months	Mean change in dysmenorrhoea: –2.3 with gonadorelin analogues v –0.3 with placebo Mean change in pelvic pain: –1.2 with gonadorelin analogues v –0.2 with placebo Mean change in dyspareunia: –0.2 with gonadorelin analogues v +0.1 with placebo
	Dydrogesterone 40 mg or 60 mg v placebo	1	62 women with endometriosis diagnosed by laparoscopy	Proportion of women with pain relief at 6 months	4/11 (36%) with dydrogesterone 40 mg v 5/11 (45%) with placebo; RR 0.80, 95% CI 0.29 to 2.21 7/10 (70%) with dydrogesterone 60 mg v 5/11 (45%) with placebo; RR 1.54, 95% CI 0.72 to 3.31
	Medroxyprogesterone acetate 100 mg daily v placebo*	1	33 women with endometriosis diagnosed by laparoscopy, who had had no previous surgical or medical endometriosis treatment	Symptom severity at 6 months	WMD –5.20, 95% CI –6.80 to –3.60
	Danazol v placebo*	1	35 women with endometriosis diagnosed by laparoscopy, who had had no previous surgical or medical endometriosis treatment	Symptom severity at 6 months	WMD –5.70, 95% CI –7.51 to –3.89

Ref, reference. *This RCT was a 3-arm trial: medroxyprogesterone acetate, danazol, and placebo.